Maze Therapeutics (NASDAQ:MAZE) CMO Sells $425,476.76 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 16,141 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $26.36, for a total value of $425,476.76. Following the sale, the chief marketing officer directly owned 16,141 shares in the company, valued at approximately $425,476.76. The trade was a 50.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Harold Bernstein also recently made the following trade(s):

• On Thursday, September 3rd, Harold Bernstein sold 5,189 shares of Maze Therapeutics stock. The stock was sold at an average price of $26.01, for a total transaction of $134,965.89.
• On Wednesday, September 2nd, Harold Bernstein sold 5,106 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.47, for a total transaction of $135,155.82.
• On Thursday, August 13th, Harold Bernstein sold 16,142 shares of Maze Therapeutics stock. The shares were sold at an average price of $27.61, for a total transaction of $445,680.62.
• On Wednesday, July 1st, Harold Bernstein sold 14,609 shares of Maze Therapeutics stock. The shares were sold at an average price of $29.90, for a total transaction of $436,809.10.

Maze Therapeutics Stock Up 1.3%

Shares of Maze Therapeutics stock opened at $26.21 on Friday. The company has a quick ratio of 18.31, a current ratio of 18.31 and a debt-to-equity ratio of 0.09. The company has a market cap of $1.46 billion, a P/E ratio of -10.40 and a beta of 2.17. The firm’s 50 day moving average price is $28.69 and its 200-day moving average price is $31.17. Maze Therapeutics, Inc. has a 52-week low of $14.27 and a 52-week high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last posted its earnings results on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, meeting analysts’ consensus estimates of ($0.76). On average, sell-side analysts predict that Maze Therapeutics, Inc. will post -2.72 EPS for the current fiscal year.

Key Stories Impacting Maze Therapeutics

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Analyst sentiment remains broadly constructive. TD Cowen upgraded MAZE to “strong buy,” BTIG reiterated a “buy” rating with a $46 price target, and the consensus rating is “buy” with an average target of $66.00. Maze Therapeutics insider trading and analyst coverage
• Neutral Sentiment: Institutional ownership activity included purchases or position increases by Royal Bank of Canada, Russell Investments Group and other firms. These holdings are relatively small, however, and are unlikely to be a major near-term price driver.
• Neutral Sentiment: Maze’s CEO Jason Coloma, CMO Harold Bernstein and other insiders sold shares between September 1 and September 3. Combined reported sales totaled roughly $2.4 million, but the filings said the transactions were made to cover tax obligations from equity vesting; Bernstein’s September 1 sale was also conducted under a pre-arranged Rule 10b5-1 plan. SEC insider trading filing
• Negative Sentiment: The scale and repetition of insider selling may weigh on investor sentiment, particularly as the CEO reduced his directly held shares substantially. MAZE has also been trading below its 50-day and 200-day moving averages, signaling continued technical weakness. The company remains loss-making, with quarterly EPS of negative $0.76 and analysts expecting approximately negative $2.72 EPS for the year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on MAZE. BTIG Research reiterated a “buy” rating and set a $46.00 price objective on shares of Maze Therapeutics in a report on Wednesday, August 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Wall Street Zen lowered Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, TD Cowen upgraded Maze Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Three research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $66.00.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. TRV GP IV LLC acquired a new stake in shares of Maze Therapeutics during the second quarter worth $133,502,907. ARCH Venture Management LLC acquired a new position in shares of Maze Therapeutics in the 2nd quarter valued at $122,983,582. BlackRock Inc. purchased a new position in Maze Therapeutics in the 2nd quarter worth $104,525,000. Jupiter Topco LLC purchased a new position in Maze Therapeutics in the 2nd quarter worth $101,764,000. Finally, Janus Henderson Group PLC lifted its position in Maze Therapeutics by 318.0% during the 4th quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock worth $130,197,000 after acquiring an additional 2,390,713 shares during the period.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.